Clinical utility of calprotectin and lactoferrin as markers of inflammation in patients with inflammatory bowel disease

References

• Stange EF, Travis SPL, Vermeire S et al. European evidence-based consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. Gut55, i1–i15 (2006).
   Google Scholar
• Stange EF, Travis SPL, Vermeire S et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. Journal of Crohn’s and Colitis2, 1–23 (2008).
   PubMed Web of Science ®Google Scholar
• Tibble JA, Bjarnason I. Non-invasive investigation of inflammatory bowel disease. World J. Gastroenterol.7(4), 460–465 (2001).
   PubMed Web of Science ®Google Scholar
• Saverymuttu SH, Camilleri M, Rees H et al. Indium 111-granulocyte scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal indium 111-granulocyte excretion. Gastroenterology90(5 Pt 1), 1121–1128 (1986).
   PubMed Web of Science ®Google Scholar
• Leddin DJ, Paterson WG, Da Costa LR et al. Indium-111-labeled autologous leukocyte imaging and faecal excretion. Comparison with conventional methods of assessment of inflammatory bowel disease. Dig. Dis. Sci.32(4), 377–387 (1987).
   PubMed Web of Science ®Google Scholar
• Roseth AG, Schmidt PN, Fagerhal MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand. J. Gastroenterol.34, 50–54 (1999).
   PubMed Web of Science ®Google Scholar
• Guerrant RL, Araujo V, Soares E et al. Measurement of fecal lactoferrin as a marker of fecal leukocytes. J. Clin. Microbiol.30, 1238–1242 (1992).
   PubMed Web of Science ®Google Scholar
• Oseas R, Yang HH, Baehner RL et al. Lactoferrin: a promoter of polymorphonuclear leucocyte adhesiveness. Blood57(5), 939–945 (1981).
   PubMed Web of Science ®Google Scholar
• Palmon R, Brown SJ, Abreu MT. What is the role and significance of serum and stool biomarkers in the diagnosis of IBD? Inflamm. Bowel Dis.14, S187–S189 (2008).
   Google Scholar
• Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut55, 426–431 (2006).
   PubMed Web of Science ®Google Scholar
• Olafsdottir E, Aksnes L, Fluge G, Bertstad A. Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children. Acta Pediatr.91(1), 45–50 (2002).
   PubMed Web of Science ®Google Scholar
• Carroccio A, Iacono G, Cottone M et al. Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhoea from irritable bowel syndrome: a prospective study in adults and children. Clin. Chem.49(6), 861–867 (2003).
   PubMed Web of Science ®Google Scholar
• Quail MA, Russel RK, Van Limbergen JE et al. Fecal calprotectin complements routine laboratory investigations in diagnosing childhood inflammatory bowel disease. Inflamm. Bowel Dis.15, 756–759 (2009).
   PubMedGoogle Scholar
• Joishy M, Davies I, Ahmed M et al. Fecal calprotectin and lactoferrin as noninvasive markers of pediatric inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr.48, 48–54 (2009).
   PubMed Web of Science ®Google Scholar
• Schoepfer AM, Trummler M, Seeholzer P, Criblez DH, Seibold F. Accuracy of four fecal assays in the diagnosis of colitis. Dis. Colon Rectum.50, 1697–1706 (2007).
   PubMed Web of Science ®Google Scholar
• Limburg PJ, Ahlquist DA, Sandborn WJ et al. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am. J. Gastroenterol.95, 2831–2837 (2000).
   PubMed Web of Science ®Google Scholar
• Schroder O, Naumann M, Shastri Y, Povse N, Stein J. Prospective evaluation of faecal neutrophil-derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin. Aliment. Pharmacol. Ther.26, 1035–1042 (2007).
   PubMed Web of Science ®Google Scholar
• Hirata I, Hoshimoto M, Saito O et al. Usefulness of faecal lactoferrin and haemoglobin in diagnosis of colorectal diseases. World J. Gastroenterol.13(10), 1569–1574 (2007).
   PubMed Web of Science ®Google Scholar
• Meucci G, D’Incà R, Maieron R et al. Diagnostic value of faecal calprotectin in unselected outpatients referred for colonoscopy: a multicenter prospective study. Dig. Liver Dis.42, 191–195 (2010).
   PubMedGoogle Scholar
• Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology123, 450–460 (2002).
   PubMed Web of Science ®Google Scholar
• Schoepfer AM, Trummler M, Seeholzer P, Seibold-Schmidt B, Seibold F. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm. Bowel Dis.14, 32–39 (2008).
   PubMed Web of Science ®Google Scholar
• Wassell J, Dolwani S, Metzner M, Losty H, Hawthorne A. Faecal calprotectin: a new marker for Crohn’s disease? Ann. Clin. Biochem.41, 230–232 (2004).
   PubMedGoogle Scholar
• Tibble J, Teahon K, Thjodleifsson B et al. A simple method for assessing intestinal inflammation in Crohn’s disease. Gut47, 506–513 (2000).
   PubMed Web of Science ®Google Scholar
• Von Roon AC, Karamountzos L, Purkayastha S et al. Diagnostic precision of faecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am. J. Gastroenterol.102, 803–813 (2007).
   PubMed Web of Science ®Google Scholar
• D’Incà R, Dal Pont E, Di Leo V et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int. J. Colorectal Dis.22, 429–437 (2007).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Hanauer SB et al. A review of activity indeced and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology122, 512–530 (2002).
   PubMed Web of Science ®Google Scholar
• Gisbert JP, McNicholl AG, Gomollon F. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. Inflamm. Bowel Dis.15, 1746–1754 (2009).
   PubMed Web of Science ®Google Scholar
• Fagerberg UL, Loof L, Lindholm J, Hansson LO, Finkel Y. Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr.45, 414–420 (2007).
   PubMed Web of Science ®Google Scholar
• Berni Canani R, Terrin G, Rapacciuolo L et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig. Liver Dis.40, 547–553 (2008).
   PubMedGoogle Scholar
• Langhorst J, Elsenbruch S, Mueller T et al. Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm. Bowel Dis.11(12), 1085–1091 (2005).
   PubMed Web of Science ®Google Scholar
• Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of faecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indexes. Am. J. Gastroenterol.103, 162–169 (2008).
   PubMed Web of Science ®Google Scholar
• Sipponen T, Karkkainen P, Savilahti E et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings. Aliment. Pharmacol. Ther.28, 1221–1229 (2008).
   PubMed Web of Science ®Google Scholar
• Sipponen T, Savilahti E, Kohlo KL, Nuutinen H, Turunen U, Farkkila M. Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findings. Inflamm. Bowel Dis.14, 40–46 (2008).
   PubMed Web of Science ®Google Scholar
• Vieira A, Fang CB, Rolim EG et al. Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Res. Notes2, 221 (2009).
   PubMedGoogle Scholar
• Schoepfer AM, Beglinger C, Straumann A et al. Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am. J. Gastroenterol.105(1), 162–169 (2010).
   PubMed Web of Science ®Google Scholar
• Schoepfer AM, Beglinger C, Straumann A, Trummler M, Renzulli P, Seibold F. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm. Bowel Dis.15, 1851–1858 (2009).
   PubMed Web of Science ®Google Scholar
• Amati L, Passeri ME, Selicato F et al. New insights into the biological and clinical significance of fecal calprotectin in inflammatory bowel disease. Immunopharmacol. Immunotoxicol.28(4), 665–681 (2006).
   PubMed Web of Science ®Google Scholar
• Walkiewicz D, Werlin SL, Fish D, Scanlon M, Hanaway P, Kugathasan S. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm. Bowel Dis.14, 669–673 (2008).
   PubMed Web of Science ®Google Scholar
• Tibble JA, Sighthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology119, 15–22 (2000).
   PubMed Web of Science ®Google Scholar
• Costa F, Mumolo MG, Ceccarelli L et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease. Gut54, 364–368 (2005).
   PubMed Web of Science ®Google Scholar
• Hanaway P, Roseth A. Inflammatory biomarkers predict relapse in IBD. Gut54, 1346–1347 (2005).
   PubMedGoogle Scholar
• D’Incà R, Dal Pont E, Di Leo V et al. Can calprotectin predict relapse risk in inflammatory bowel disease? Am. J. Gastroenterol.103, 2007–2014 (2008).
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Bermejo F, Pérez-Calle JL et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm. Bowel Dis.15(8), 1190–1198 (2009).
   PubMed Web of Science ®Google Scholar
• Ho GT, Lee HM, Brydon G et al. Fecal calprotectin predicts the clinical course of acute severe colitis. Am. J. Gastroenterol.104, 673–678 (2009).
   PubMed Web of Science ®Google Scholar
• Damms A, Bischoff SC. Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases. Int. J. Colorectal. Dis.23, 985–992 (2008).
   PubMed Web of Science ®Google Scholar
• Elkjaer M, Burisch J, Voxen Hansen V et al. A new rapid home test for faecal calprotectin in ulcerative colitis. Aliment. Pharmacol. Ther.31(2), 323–330 (2010).
   PubMed Web of Science ®Google Scholar
• Buderus S, Boone J, Lyerly D, Lentze MJ. Fecal lactoferrin: a new parameter to monitor infliximab therapy. Dig. Dis. Sci.49(6), 1036–1039 (2004).
   PubMed Web of Science ®Google Scholar
• Sipponen T, Savilahti E, Karkkainen P et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-α therapy for Crohn’s disease. Inflamm. Bowel Dis.14(10), 1392–1398 (2008).
   PubMed Web of Science ®Google Scholar
• Wagner M, Peterson CGB, Ridefelt P, Sangfelt P, Carlson M. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J. Gastroenterol.14(36), 5584–5589 (2008).
   PubMed Web of Science ®Google Scholar
• Kolho KL, Raivio T, Lindahl H, Savilahti E. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease. Scand. J. Gastroenterol.41, 720–725 (2006).
   PubMed Web of Science ®Google Scholar
• Sipponen T, Bjokesten CLA, Farkkila M et al. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn’s disease treatment. Scand. J. Gastroenterol.45(3), 325–331 (2009).
   Google Scholar
• Orlando A, Modesto I, Castiglione F et al. The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn’s disease: a comparison with ultrasound. Eur. Rev. Med. Pharmacol. Sci.10(1), 17–22 (2006).
   PubMedGoogle Scholar
• Lamb CA, Mohiuddin MK, Gicquel J et al. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn’s disease. Br. J. Surg.96, 663–674 (2009).
   PubMed Web of Science ®Google Scholar
• Scarpa M, D’Incà R, Basso D et al. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn’s disease. Dis. Colon Rectum.50, 861–867 (2007).
   PubMed Web of Science ®Google Scholar
• Ruffolo C, Scarpa M, Faggian D et al. Subclinical intestinal inflammation in patients with Crohn’s disease following bowel resection: a smoldering fire. J. Gastrointest. Surg.14, 24–31 (2010).
   PubMedGoogle Scholar
• Navaneethan U, Shen B. Laboratory tests for patients with ileal–pouch–anal anastomosis: clinical utility in predicting, diagnosing, and monitoring pouch disorders. Am. J. Gastroenterol.104(10), 2606–2615 (2009).
   PubMedGoogle Scholar
• Thomas P, Rihani H, Roseth A et al. Assessment of ileal pouch inflammation by single-stool calprotectin assay. Dis. Colon Rectum43, 214–220 (2000).
   PubMed Web of Science ®Google Scholar
• Johnson MW, Maestranzi S, Duffy AM et al. faecal calprotectin: a noninvasive diagnostic tool and marker of severity in pouchitis. Eur. J. Gastroenterol. Hepatol.20, 174–179 (2008).
   PubMed Web of Science ®Google Scholar
• Parsi MA, Shen B, Achar JP et al. Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch–anal anastomosis. Gastroenterology126, 1280–1286 (2004).
   PubMed Web of Science ®Google Scholar
• Lim M, Gonsalves S, Thekkinkattil D et al. The assessment of a rapid non invasive immunochromatographic assay test for fecal lactoferrin in patients with suspected inflammation of the ileal pouch. Dis. Colon Rectum51(1), 96–99 (2008).
   PubMedGoogle Scholar
• Pakarinen MP, Koivusalo A, Natunen J et al. Fecal calprotectin mirrors inflammation of the distal ileum and bowel function after restorative proctocolectomy for pediatric-onset ulcerative colitis. Inflamm. Bowel Dis.13(3), 482–486 (2009).
   Google Scholar